Bank of America Securities Raises HengAn International Price Target to HK$30, Anticipates 8% Core Net Profit Growth in Second Half of Last Year

Deep News02-11 16:33

Bank of America Securities issued a research report stating that it has lowered its core net profit forecasts for HENGAN INT'L (01044) by 3% and 1% for 2025 and 2026, respectively. However, due to an improved competitive landscape in the industry, the target price-to-earnings ratio has been raised to 13 times, leading to an 18% increase in the target price to HK$30. Although the company lacks long-term growth catalysts, it offers an attractive dividend yield. The "Neutral" rating was reaffirmed.

The institution expects HENGAN INT'L's revenue for the second half of 2025 to grow 1% year-on-year to RMB 10.9 billion, driven by continued improvement across its three main business segments. Tissue product sales are projected to increase by 5% year-on-year, accelerating from the 3% growth seen in the first half. Additionally, the gross profit margin for the second half is expected to rise compared to the first half, reaching 33.1%, primarily due to improved product mix and normalized raw material costs in the tissue business. Core net profit for the second half of 2025 is forecasted to grow 8% year-on-year to RMB 1 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment